.jpeg)
2026-07-22 04:17:54
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates endogenous erythropoietin production by mimicking the physiological response to hypoxia, offering an injection-free treatment option for patients with chronic kidney disease-related anemia. This article systematically reviews its mechanism of action, clinical efficacy, and safety profile.
2026-07-22 04:06:31
Ponatinib and olverembatinib are both third-generation BCR-ABL tyrosine kinase inhibitors effective against the T315I gatekeeper mutation. This article provides a systematic comparison across target coverage, clinical efficacy, cardiovascular safety, and dosing strategies to inform treatment decisions.
2026-07-21 07:22:56
A balanced review of leflunomide-related eye symptoms, incidence, monitoring recommendations, and management strategies for rheumatoid arthritis patients.
2026-07-21 07:17:20
A structured overview of progression criteria, molecular profiling, and sequential treatment strategies following resistance to garsorasib in advanced NSCLC.
2026-07-20 07:28:12
Capivasertib is an oral AKT inhibitor with molecular formula C₂₁H₂₅ClN₆O₂, selectively binding to AKT protein to block PI3K/AKT signaling, used in precision therapy for breast cancer and other tumors.
2026-07-20 07:25:47
Avatrombopag is an oral thrombopoietin receptor agonist indicated for chronic liver disease-associated thrombocytopenia and chronic immune thrombocytopenia (ITP) in adults and children aged 1 year and older, promoting platelet production via bone marrow stimulation.
2026-07-20 07:22:46
Capivasertib is an oral AKT inhibitor used to treat breast cancer and prostate cancer. This article compares the original brand and generic versions from Laos, highlighting differences in price, composition, and considerations for selection.
2026-07-20 07:19:23
Gilteritinib is an oral FLT3 inhibitor specifically indicated for adult patients with FLT3 mutation-positive relapsed or refractory acute myeloid leukemia (AML), precisely blocking abnormal signaling pathways to achieve targeted treatment.
2026-07-17 07:15:40
Learn how Macitentan (Opsumit) fits into PAH management. This guide covers dietary compatibility, critical warnings against St. John’s Wort, drug-drug interactions, and mandatory contraception requirements.
2026-07-17 07:10:28
This article analyzes the 2026 FDA approval of Selumetinib for adult Neurofibromatosis Type 1 (NF1) with symptomatic plexiform neurofibromas (PN). Covering KOMET Phase III data, BSA-based dosing, hepatic impairment adjustments, and global market availability, it serves as a comprehensive guide for clinicians.
2026-07-16 07:37:00
This guide details the essential baseline evaluations and proactive management strategies for patients starting Lenvatinib therapy. It covers hypertension, proteinuria, hypothyroidism, hand-foot skin reactions, cardiac monitoring, and drug interactions.
2026-07-16 07:21:04
This article summarizes adverse reactions associated with donidalorsen (DAWNZERA®) for prophylaxis of hereditary angioedema (HAE) attacks in patients aged 12 and older, including injection site reactions, upper respiratory tract infection, urinary tract infection, abdominal discomfort, hypersensitivity reactions, and monitoring of platelet/liver function, with safety notes for patients and clinicians.
